Furthermore, Nyken is aiming to engage in partnering programs and strategic alliances with pharmaceutical companies to develop our selected drug candidates up to the clinic. Nyken is interested to in-license novel compounds or technologies for other HSF1- and Hsp-related targets. Interested investors, strategic partners for research collaborations and requests for out- and in-licensing, should contact Chief Executive Officer Dr. Herman Steen at This email address is being protected from spambots.
View Top Employees from Nyken| Website | http://www.nyken.com |
| Revenue | $4 million |
| Employees | View employees |
| Address | Meditech Center Umcg, L.J. Zielstraweg 1, Groningen, Groningen, NL |
| Industry | Pharmaceuticals, Healthcare, Biotechnology, Drug Manufacturing & Research |
| SIC | SIC Code 2834 Companies, SIC Code 28 Companies, SIC Code 283 Companies |
| NAICS | NAICS Code 325 Companies, NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies |
Looking for a particular Nyken employee's phone or email?
Nyken Questions
The Nyken annual revenue was $4 million in 2023.
Nyken is based in Groningen, Groningen.
The NAICS codes for Nyken are [325, 3254, 32541, 32].
The SIC codes for Nyken are [2834, 28, 283].
